Single-domain antibodies against CD33 and constructs thereof

US12275788B2 · kind B2 · utility

Assignee

• Legend Biotech Ireland Limited · IE

Inventors

• Yafeng Zhang · 安丰镇, CN
• Tailan Zhan · 安丰镇, CN
• Fei Sun · Shanghai, CN
• Jian Liu · Chapel Hill, US
• Qing Zhang · Short Hills, US
• Shu Wu · Nanjing, CN

Key dates

• Filing date: Sep 10, 2019
• Grant date: Apr 15, 2025
• Expiry date: Aug 11, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2510/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present application provides single-domain antibodies targeting CD33 and constructs thereof, including chimeric receptors, immune effector cell engagers and immunoconjugates. Further provided are engineered immune cells (such as T cells) comprising an anti-CD33 chimeric receptor and optionally a second chimeric receptor targeting a second antigen or epitope. Pharmaceutical compositions, kits and methods of treating cancer are also provided.